Surgical issues after neoadjuvant treatment for gastric cancer
- PMID: 20496541
Surgical issues after neoadjuvant treatment for gastric cancer
Abstract
Gastric carcinoma is one of the most frequent malignancies in the world and its clinical behavior depends on the metastatic potential of the tumour. Particularly, lymphatic metastasis is one of the main predictor of tumour recurrence and survival and current pathologic staging systems reflect the concept that lymphatic spread is the most relevant prognostic factor in patients resected with curative intent. This is deducted by the observation that two thirds of gastric cancers in the western world present at an advanced stage, with nearly 85% of tumors accompanied by lymph node metastasis at diagnosis. To date most therapeutic efforts are directed toward individualization of therapeutic protocols, tailoring the extent of resection integrated by the administration of preoperative and postoperative treatment. The goal of such strategies is to improve prognosis towards the achievement of a curative resection (R0-resection) with minimal morbidity and mortality, with better postoperative quality of life. A brief review of literature about preoperative therapy for gastric carcinoma will be herein illustrated. The rationale and the general drawbacks of preoperative treatments will be both discussed in order to demonstrate its value in terms of safety and efficacy.
Similar articles
-
Adjuvant and neoadjuvant therapy for gastric cancer.Semin Oncol. 1996 Jun;23(3):379-89. Semin Oncol. 1996. PMID: 8658222 Review.
-
Current status and future perspectives in gastric cancer management.Cancer Treat Rev. 2000 Aug;26(4):243-55. doi: 10.1053/ctrv.2000.0164. Cancer Treat Rev. 2000. PMID: 10913380 Review.
-
[The value of adjuvant and neoadjuvant chemotherapy in treatment of stomach carcinoma].Wien Klin Wochenschr. 1996;108(16):496-504. Wien Klin Wochenschr. 1996. PMID: 8967093 Review. German.
-
R0 resection in the treatment of gastric cancer: room for improvement.World J Gastroenterol. 2010 Jul 21;16(27):3358-70. doi: 10.3748/wjg.v16.i27.3358. World J Gastroenterol. 2010. PMID: 20632437 Free PMC article.
-
Outcome of patients with known metastatic gastric cancer undergoing resection with therapeutic intent.Ann Surg Oncol. 2007 Feb;14(2):365-72. doi: 10.1245/s10434-006-9059-z. Ann Surg Oncol. 2007. PMID: 17146744
Cited by
-
Curcumin Analog CH-5 Suppresses the Proliferation, Migration, and Invasion of the Human Gastric Cancer Cell Line HGC-27.Molecules. 2018 Jan 30;23(2):279. doi: 10.3390/molecules23020279. Molecules. 2018. PMID: 29385675 Free PMC article.
-
Down-regulation of miR-622 in gastric cancer promotes cellular invasion and tumor metastasis by targeting ING1 gene.World J Gastroenterol. 2011 Apr 14;17(14):1895-902. doi: 10.3748/wjg.v17.i14.1895. World J Gastroenterol. 2011. PMID: 21528065 Free PMC article.
-
G-protein coupled receptor 34 knockdown impairs the proliferation and migration of HGC-27 gastric cancer cells in vitro.Chin Med J (Engl). 2015 Feb 20;128(4):545-9. doi: 10.4103/0366-6999.151114. Chin Med J (Engl). 2015. PMID: 25673461 Free PMC article.
-
Clinicopathologic Implications of Eukaryotic Initiation Factor 3f and Her-2/neu Expression in Gastric Cancer.Clin Transl Sci. 2015 Aug;8(4):320-5. doi: 10.1111/cts.12263. Epub 2015 Feb 14. Clin Transl Sci. 2015. PMID: 25684180 Free PMC article.
-
Decreased expression of eukaryotic initiation factor 3f is an adverse prognostic factor for stage I-III gastric cancer.World J Surg Oncol. 2014 Mar 28;12:72. doi: 10.1186/1477-7819-12-72. World J Surg Oncol. 2014. PMID: 24678890 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical